Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.
Jacob A Lowy, Michael F Rogers, Zachary M Avigan...
https://pubmed.ncbi.nlm.nih.gov/41708325/Actively Recruiting
Led by Regeneron Pharmaceuticals · Updated on 2026-10-26
387
Participants Needed
40
Research Sites
11 weeks
Total Duration
Researchers are studying linvoseltamab, a drug being evaluated for safety, best dosing, and potential effectiveness in treating adults with relapsed or refractory multiple myeloma. This study aims to understand side effects, how the drug behaves in the body, its blood levels, and its ability to treat cancer. The trial includes patients who have had multiple prior treatments and may have exhausted standard options. The study is divided into phases with different treatment approaches. Phase 1 has two parts dose escalation with intravenous IV linvoseltamab and subcutaneous SC administration. Participants may receive low or high doses of IV monotherapy or high doses with anti-interleukin-6 receptor prophylactic therapy. Phase 2 includes several cohorts receiving linvoseltamab monotherapy. The drug is administered according to the study protocol. Participants undergo evaluations to monitor safety and effects, including observation of dose-limiting toxicities within 28 days and treatment-emergent adverse events for up to 5 years. Researchers track blood levels of linvoseltamab, immune responses, objective response rates, and quality of life measures. The study includes detailed follow-up of health status and symptoms, lasting up to 5 years after treatment begins to assess long-term outcomes and safety.
CONDITIONS
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
C
Clinical Trial Administrator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Regeneron Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Linvoseltamab | Current care options |
|---|---|---|
| What it is | A BCMA×CD3 bispecific antibody given in escalating and expansion dose cohorts to treat heavily pretreated relapsed/refractory multiple myeloma | Established treatment options include BCMA‑targeted CAR‑T cell therapy, other BCMA‑directed bispecific antibodies, or triplet regimens with proteasome inhibitors, immunomodulators, and anti‑CD38 antibodies |
| Role in trial | Investigational treatment tested sequentially in Phase 1/2 dose‑escalation and expansion cohorts | Not part of this trial |
| Primary use | Treated adults with relapsed/refractory multiple myeloma after at least three prior therapy lines or triple‑refractory status | Used as salvage therapy in similar relapsed/refractory myeloma patients |
| How it is given or performed | Administered per protocol across escalating and full‑dose cohorts (e.g. intravenous bispecific antibody dosing) | Varies by regimen—CAR‑T involves cell infusion, bispecifics involve intravenous or subcutaneous dosing, triplets combine oral and infusible agents |
| Evidence status | Showed high response rates and manageable safety in heavily pretreated patients in LINKER‑MM1 (ORR ~70%; CR≥50%; median DoR ≈29 months; median OS ≈31 months) | BCMA CAR‑T and bispecifics, as well as triplet regimens, have demonstrated durable remissions and are now guideline‑recommended options |
| Important risks | Safety profile includes treatment‑emergent adverse events and cytokine release syndrome; generally manageable | CAR‑T and bispecifics carry class‑specific risks including CRS, neurotoxicity, hematotoxicity; triplets have known chemotherapy‑related toxicities |
| Important limitations | Single‑arm design without comparator limits direct efficacy comparison; long‑term outcomes beyond current follow‑up are pending | Access to BCMA CAR‑T or bispecifics may be limited by manufacturing, cost, or availability; triplets may be less effective in triple‑refractory disease |
| Patient impact | Reported durable responses and prolonged survival suggest meaningful potential benefit for heavily pretreated patients | Established therapies in similar patients offer durable remissions and are accessible in current practice |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits
Duration - Up to 5 years
Participants receive linvoseltamab through intravenous or subcutaneous methods according to the study phase, with varying dosing levels including low dose, high dose, and high dose with anti-IL-6 receptor prophylaxis.
Regular visits as per protocol
Duration - Up to 5 years
Participants are monitored for safety, side effects, drug levels in blood, and response to treatment through assessments and questionnaires lasting up to 5 years after starting treatment.
Periodic visits and evaluations
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Jacob A Lowy, Michael F Rogers, Zachary M Avigan...
https://pubmed.ncbi.nlm.nih.gov/41708325/Hans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar...
https://pubmed.ncbi.nlm.nih.gov/41387038/Naresh Bumma, Joshua Richter, Sundar Jagannath...
https://pubmed.ncbi.nlm.nih.gov/38879802/James E Hoffman, Naresh Bumma, Joshua Richter...
https://pubmed.ncbi.nlm.nih.gov/42564571/Regeneron Pharmaceuticals
Lead Sponsor